echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The role of genetic testing in the prevention and treatment of ovarian cancer from the perspective of genetics

    The role of genetic testing in the prevention and treatment of ovarian cancer from the perspective of genetics

    • Last Update: 2021-08-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The famous American movie star Angelina Jolie wrote an article "My Medical Choices" in May 2013, claiming that through genetic testing, she was determined to carry the BRCA1 mutation.


    BRCA gene is the top priority of genetic testing for hereditary ovarian cancer

    BRCA gene is the top priority of genetic testing for hereditary ovarian cancer

    Personal genetic factors play an important role in the occurrence and development of tumors, and determine the susceptibility of individuals to tumors


    In all ovarian cancer patients, HBOCS accounts for 10%-15%.


    BRCA mutation is the gold standard for opening first-line maintenance treatment of ovarian cancer with PARP inhibitors

    BRCA mutation is the gold standard for opening first-line maintenance treatment of ovarian cancer with PARP inhibitors

    A study of patients with hereditary ovarian cancer found that patients with BRCA1/2 gene pathogenic mutations usually have a better prognosis.


    Based on the outstanding results of the PARP inhibitor olaparib SOLO-1, the FDA quickly approved it as a long-term maintenance treatment for patients with BRCA-mutated ovarian cancer, fallopian tube cancer, and primary peritoneal cancer after first-line chemotherapy after reaching PR or CR after first-line chemotherapy


    Figure 1.


    It should be noted that although the follow-up time of the SOLO1 study is 5 years, the median treatment time of the olaparib group is only 24.


    Figure 2.


    The BRCA1/2 gene is the most important biomarker to assess the risk of ovarian cancer and influence the choice of individualized treatment options for patients.


    HRD testing expands groups benefiting from maintenance therapy with PARP inhibitors for ovarian cancer

    HRD testing expands groups benefiting from maintenance therapy with PARP inhibitors for ovarian cancer

    As mentioned earlier, in addition to the BRCA1/2 gene, there are many genes that are closely related to the occurrence and development of ovarian cancer


    In summary, genetic testing of patients with ovarian cancer and screening for pathogenic mutations can help doctors perform precise treatments on patients.


    【references】

    [1[Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.


    [2]2020 ESMO Abs 811MO

    [3]2020 "NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian"

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.